media – Page 675 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Meeting the Internet of Medical Things’ Demands for Networking

More connected medical devices are coming online every day, reshaping the way that healthcare networks are designed, used and secured.
- Source: healthtechmagazine.net
- 505
- November 22, 2017
Internet of Things Researches
Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data

Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
- Source: biospace
- 637
- November 22, 2017
cancer CAR–T immuno-oncology Researches
FDA approves first two-drug regimen for certain patients with HIV

The U.S. Food and Drug Administration(FDA) today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
- Source: finance.yahoo
- 533
- November 22, 2017
FDA HIV immunodeficiency Juluca New Approvals
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight in a mid-stage study, top researchers at Novo Nordisk today unveiled an ambitious late-stage strategy to make their mark in a tough, but potentially blockbuster market.
- Source: endpts
- 624
- November 22, 2017
Company Insight Novo Nordisk semaglutide
NHS England consults on simplifying research processes

NHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”.
- Source: Pharmatimes
- 508
- November 22, 2017
NHS polices
FDA OKs Genentech’s Gazyva for Untreated Follicular Lymphoma

Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
- Source: Biospace
- 665
- November 21, 2017
cancer FDA hemophilia lymphoma New Approvals
Japan’s PeptiDream Bags $1.11B+ R&D Pact With Bayer

Peptidream Inc. has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
- Source: Biospace
- 551
- November 21, 2017
Market Views PDC PDPS peptide-based
CRISPR shows potential to reduce diseases spread by mosquitoes

Researchers at the University of California, Riverside, have shown that it is possible for transgenic mosquitos to stably express the Cas9 enzyme in their germline. Cas9 addition will allow the utilization of the CRISPR gene editing tool to carry out efficient and highly targeted changes to the DNA of the mosquitoes.
- Source: news-medical
- 581
- November 21, 2017
CAS9 CRISPR DNA enzyme Researches
For the First Time, a Robot Passed a Medical Licensing Exam

Experts generally agree that, before we might consider artificial intelligence (AI) to be truly intelligent —that is, on a level on par with human cognition— AI agents have to pass a number of tests. And while this is still a work in progress, AIs have been busy passing other kinds of tests.
- Source: futurism
- 547
- November 21, 2017
Artificial Intelligence
UNAIDS announces nearly 21 million people living with HIV now on treatment

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy. By June 2017, around 20.9 million people had access to the life-saving medicines. Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment.
- Source: reliefweb
- 487
- November 21, 2017
antiretroviral HIV UNAIDS

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.